Literature DB >> 3082922

Association with phagocytic inhibition of anti-Pseudomonas aeruginosa immunoglobulin G antibody subclass levels in serum from patients with cystic fibrosis.

T R Shryock, J S Mollé, J D Klinger, M J Thomassen.   

Abstract

Serum from cystic fibrosis patients colonized with Pseudomonas aeruginosa specifically inhibits phagocytosis of P. aeruginosa by alveolar macrophages. Serum was examined for P. aeruginosa lipopolysaccharide-specific immunoglobulin G (IgG) subclass levels (by enzyme-linked immunosorbent assay) and for the effect on macrophage phagocytosis (by radiolabeled P. aeruginosa uptake). Sera from cystic fibrosis patients with no known P. aeruginosa colonization history had negligible amounts of lipopolysaccharide-specific IgG and a mean phagocytic enhancement of 5%. The sera of normal volunteers also had negligible amounts of lipopolysaccharide-specific IgG. Serum from cystic fibrosis patients with P. aeruginosa respiratory tract infections had substantial titers (range, 1:20 to 1:1,280) of lipopolysaccharide-specific IgG2, IgG3, and IgG4 and a mean phagocytic inhibition of 56%. However, these patients had low or absent titers of lipopolysaccharide-specific IgG1. No consistent variation in the level of individual IgG subclasses in the sera of colonized patients was observed, as determined by radial immunodiffusion. The results suggest that during P. aeruginosa infection phagocytosis-inhibitory activity develops coincident with production of lipopolysaccharide-specific IgG subclasses.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3082922      PMCID: PMC268685          DOI: 10.1128/jcm.23.3.513-516.1986

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  17 in total

1.  Elevated serum IgG4 levels in cystic fibrosis patients.

Authors:  F Shakib; D R Stanworth; C A Smalley; G A Brown
Journal:  Clin Allergy       Date:  1976-05

Review 2.  Cystic fibrosis.

Authors:  R E Wood; T F Boat; C F Doershuk
Journal:  Am Rev Respir Dis       Date:  1976-06

3.  IgG subclass levels in infancy and childhood.

Authors:  V A Oxelius
Journal:  Acta Paediatr Scand       Date:  1979-01

4.  A quantitative study of the distribution of IgG sub-classes in a group of normal human sera.

Authors:  F Shakib; D R Stanworth; R Drew; D Catty
Journal:  J Immunol Methods       Date:  1975       Impact factor: 2.303

5.  Microtiter immunoenzymatic assay (micro-ELISA) for antigen-specific IgG4 subclass antibody.

Authors:  Y P Hsu; R B Moss
Journal:  Clin Rev Allergy       Date:  1983-06

6.  Immunoglobulin subclasses in normal children.

Authors:  P H Schur; F Rosen; M E Norman
Journal:  Pediatr Res       Date:  1979-03       Impact factor: 3.756

7.  Receptors for immunoglobulin and complement on human alveolar macrophages.

Authors:  H Y Reynolds; J P Atkinson; H H Newball; M M Frank
Journal:  J Immunol       Date:  1975-06       Impact factor: 5.422

8.  Natural infection of man with group A streptococci. Levels; restriction in class, subclass, and type; and clonal appearance of polysaccharide-group-specific antibodies.

Authors:  W F Riesen; F Skvaril; D G Braun
Journal:  Scand J Immunol       Date:  1976       Impact factor: 3.487

9.  The binding of human and guinea-pig IgG subclasses to homologous macrophage and monocyte Fc receptors.

Authors:  M D Alexander; J A Andrews; R G Leslie; N J Wood
Journal:  Immunology       Date:  1978-07       Impact factor: 7.397

10.  Studies on human antibodies. VI. Selective variations in subgroup composition and genetic markers.

Authors:  W J Yount; M M Dorner; H G Kunkel; E A Kabat
Journal:  J Exp Med       Date:  1968-03-01       Impact factor: 14.307

View more
  10 in total

Review 1.  Inflammation in the lung in cystic fibrosis. A vicious cycle that does more harm than good?

Authors:  M Berger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

2.  IgG subclass antibodies to Pseudomonas aeruginosa in sera from patients with chronic Ps. aeruginosa infection investigated by ELISA.

Authors:  T Pressler; S S Pedersen; F Espersen; N Høiby; C Koch
Journal:  Clin Exp Immunol       Date:  1990-09       Impact factor: 4.330

Review 3.  Antibody-Dependent Enhancement of Bacterial Disease: Prevalence, Mechanisms, and Treatment.

Authors:  Von Vergel L Torres; Carrie F Coggon; Timothy J Wells
Journal:  Infect Immun       Date:  2021-03-17       Impact factor: 3.441

4.  Antilipopolysaccharide antibodies and differential diagnosis of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.

Authors:  A Fomsgaard; B Dinesen; G H Shand; T Pressler; N Høiby
Journal:  J Clin Microbiol       Date:  1989-06       Impact factor: 5.948

5.  The immunoglobulin G subclass composition of immune complexes in cystic fibrosis. Implications for the pathogenesis of the Pseudomonas lung lesion.

Authors:  D B Hornick; R B Fick
Journal:  J Clin Invest       Date:  1990-10       Impact factor: 14.808

6.  Nonopsonic antibodies in cystic fibrosis. Pseudomonas aeruginosa lipopolysaccharide-specific immunoglobulin G antibodies from infected patient sera inhibit neutrophil oxidative responses.

Authors:  I Eichler; L Joris; Y P Hsu; J Van Wye; R Bram; R Moss
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

Review 7.  Cystic fibrosis. Infection and immunity to Pseudomonas.

Authors:  R U Sorensen; R L Waller; J D Klinger
Journal:  Clin Rev Allergy       Date:  1991 Spring-Summer

8.  Immunoglobulin allotypes and IgG subclass antibody response to Pseudomonas aeruginosa antigens in chronically infected cystic fibrosis patients.

Authors:  T Pressler; J P Pandey; F Espersen; S S Pedersen; A Fomsgaard; C Koch; N Høiby
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

9.  Anti-Pseudomonas aeruginosa IgG subclass titers in patients with cystic fibrosis: correlations with pulmonary function, neutrophil chemotaxis, and phagocytosis.

Authors:  R G Cowan; G B Winnie
Journal:  J Clin Immunol       Date:  1993-09       Impact factor: 8.317

10.  Elevated IgG4 serum levels in patients with cystic fibrosis.

Authors:  Axelle Clerc; Quitterie Reynaud; Stéphane Durupt; Colette Chapuis-Cellier; Raphaële Nové-Josserand; Isabelle Durieu; Jean Christophe Lega
Journal:  PLoS One       Date:  2017-09-18       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.